Alaunos Therapeutics (TCRT) Gains from Sales and Divestitures (2010 - 2018)
Alaunos Therapeutics (TCRT) reported Gains from Sales and Divestitures of $573340.0 for Q3 2018, up 63.81% on a YoY basis from $350000.0 in Q3 2017, and up 6.41% quarter-over-quarter from $538824.0 in Q2 2018.
Alaunos Therapeutics (TCRT) Gains from Sales and Divestitures (2010 - 2018) Analysis & Trends
Alaunos Therapeutics has reported Gains from Sales and Divestitures for 9 years, with the latest figure at $573340.0 in Q3 2018.
- For the quarter ending Q3 2018, Gains from Sales and Divestitures rose 63.81% year-over-year to $573340.0; the trailing twelve-month figure through Sep 2018 stood at $573340.0 (up 63.81% YoY), and the FY2017 full-year result was $778965.0, up 26.11% from the prior year.
- Gains from Sales and Divestitures for Q3 2018 stood at $573340.0, up from $538824.0 in the prior quarter.
- The five-year high for Gains from Sales and Divestitures was $778965.0 in Q4 2017, with the low at $48433.0 in Q1 2014.
- Historically, Gains from Sales and Divestitures has averaged $285443.0 across 5 years, with a median of $253835.0 in 2014.
- Annual changes were most pronounced in 2014 — Gains from Sales and Divestitures tumbled 65.11% — and 2016, when it soared 393.02%.
- Alaunos Therapeutics' Gains from Sales and Divestitures stood at $253835.0 in 2014, then tumbled by 41.42% to $148694.0 in 2015, then jumped by 315.39% to $617666.0 in 2016, then advanced by 26.11% to $778965.0 in 2017, then decreased by 26.4% to $573340.0 in 2018.
- The last three Gains from Sales and Divestitures figures came in at $573340.0 (Q3 2018), $538824.0 (Q2 2018), and $205491.0 (Q1 2018), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Alaunos Therapeutics | 4.31 Mn | 3.95 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2018 | 573,340.00 |
| Sep 30, 2018 | 573,340.00 |
| Jun 30, 2018 | 538,824.00 |
| Jun 30, 2018 | 538,824.00 |
| Mar 31, 2018 | 205,491.00 |
| Mar 31, 2018 | 205,491.00 |
| Dec 31, 2017 | 778,965.00 |
| Dec 31, 2017 | 778,965.00 |
| Sep 30, 2017 | 350,000.00 |
| Sep 30, 2017 | 350,000.00 |
| Jun 30, 2017 | 350,000.00 |
| Jun 30, 2017 | 350,000.00 |
| Dec 31, 2016 | 617,666.00 |
| Dec 31, 2016 | 617,666.00 |
| Sep 30, 2016 | 350,000.00 |
| Sep 30, 2016 | 350,000.00 |
| Jun 30, 2016 | 350,000.00 |
| Jun 30, 2016 | 350,000.00 |
| Dec 31, 2015 | 148,694.00 |
| Dec 31, 2015 | 148,694.00 |